Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | NPC1 | O15118 | 8/20 | 0.59 |
| ▸ | RAB9A | P51151 | 7/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14645193 | 0.98 | ALDH1A1 (0.69) | ALDH1A1NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL64153 | 0.94 | ALDH1A1 (0.64) | ALDH1A1NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL29245012 | 0.92 | ALDH1A1 (0.62) | ALDH1A1NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL2951325 | 0.86 | ALDH1A1 (0.71) | ALDH1A1NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL20897465 | 0.86 | ALDH1A1 (0.71) | ALDH1A1NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL30277672 | 0.85 | CA1 (0.61) | ALDH1A1NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL5742108 | 0.84 | ALDH1A1 (0.69) | ALDH1A1NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL63698 | 0.83 | MAPT (0.63) | ALDH1A1NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL3025580 | 0.83 | ALDH1A1 (0.63) | ALDH1A1NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL12551037 | 0.83 | ALDH1A1 (1.00) | ALDH1A1NPC1RAB9ASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118146176-B | GPR133/ADGRD1 agonist, preparation method and application thereof | 山东大学 | 2024-11-15 | — | — | CN | disclosed |
| CN-118239923-A | Compounds useful as inhibitors of factor XIIa, pharmaceutical compositions and uses thereof | 合肥工业大学 | 2024-06-25 | — | — | CN | disclosed |
| CN-118146176-A | GPR133/ADGRD1 agonist, preparation method and application thereof | 山东大学 | 2024-06-07 | — | — | CN | disclosed |
| US-20230416228-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEWYORK | 2023-12-28 | — | — | US | disclosed |
| US-11834432-B2 | Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-12-05 | — | — | US | disclosed |
| US-11834432-B2 | Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-12-05 | — | — | US | disclosed |
| EP-4217355-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | Forkhead Biotherapeutics, inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-110835334-B | Indole-substituted azole compound and application thereof | 中国药科大学 | 2022-10-18 | — | — | CN | disclosed |
| CN-110835333-B | Benzimidazole substituted azole compound and application thereof | 中国药科大学 | 2022-10-18 | — | — | CN | disclosed |
| WO-2022066938-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | FORKHEAD BIOTHERAPEUTICS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| US-7229987-B2 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | ELI LILLY AND COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | AMMENN ET AL, JOCHEN | 2005-12-08 | — | — | US | disclosed |
| US-20050267129-A1 | Dipeptide nitrile cathepsin K inhibitors | NORVARTIS AG (CH) | 2005-12-01 | — | — | US | disclosed |
| EP-1505968-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003097047-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2003-11-27 | — | — | WO | disclosed |
| US-6642239-B2 | Compounds such as N-(1-(cyanomethylcarbamoyl)cyclohexyl)-4-(piperazin-1-yl)-benzamide | NOVARTIS AG (CH) | 2003-11-04 | — | — | US | disclosed |
| US-20030203919-A1 | Dipeptide nitrile cathepsin K inhibitors | MISSBACH MARTIN (CH) | 2003-10-30 | — | — | US | disclosed |
| EP-1254124-A1 | DIPEPTIDE NITRILE CATHPSIN K INHIBITORS | Novartis AG (CH) | 2002-11-06 | — | — | EP | disclosed |
| US-20010016207-A1 | Dipeptide nitrile cathepsin K inhibitors | NOVARTIS AG (CH) | 2001-08-23 | — | — | US | disclosed |
| WO-2001058886-A1 | DIPEPTIDE NITRILE CATHEPSIN K INHIBITORS | NOVARTIS AG (CH) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416228-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | FOXO1, FOXO3, GCKR | ALDH1A1 3526/4885NPC1 1891/4885RAB9A 1754/4885 |
| US-20030203919-A1 | Dipeptide nitrile cathepsin K inhibitors | CTSK, CTSC, CTSS | ALDH1A1 2798/4885NPC1 64/4885RAB9A 811/4885 |
| US-20050267129-A1 | Dipeptide nitrile cathepsin K inhibitors | CTSK, CTSL, CTSV | ALDH1A1 2814/4885NPC1 74/4885RAB9A 1825/4885 |
| US-20010016207-A1 | Dipeptide nitrile cathepsin K inhibitors | CTSK, CTSC, CTSS | ALDH1A1 2798/4885NPC1 64/4885RAB9A 811/4885 |
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | MC1R, MC4R, MC5R | ALDH1A1 716/4885NPC1 457/4885RAB9A 1063/4885 |
| US-11834432-B2 | Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof | NOS2, NOS1, NOS3 | ALDH1A1 1897/4885NPC1 3672/4885RAB9A 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.